Access cutting-edge pneumococcal disease treatment through this clinical trial at a research site in New Orleans. Study-provided care at no cost to qualified participants.
Access pneumococcal disease specialists in New Orleans at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pneumococcal disease treatment provided free
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study dur
Sponsor: Sanofi
Check if you qualify for this pneumococcal disease clinical trial in New Orleans, LA
If you're searching for pneumococcal disease treatment options in New Orleans, LA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Orleans research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pneumococcal disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.